230 related articles for article (PubMed ID: 31480361)
21. MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas.
Missiaglia E; Shepherd CJ; Aladowicz E; Olmos D; Selfe J; Pierron G; Delattre O; Walters Z; Shipley J
Cancer Lett; 2017 Jan; 385():251-260. PubMed ID: 27984116
[TBL] [Abstract][Full Text] [Related]
22. P/CAF mediates PAX3-FOXO1-dependent oncogenesis in alveolar rhabdomyosarcoma.
Bharathy N; Suriyamurthy S; Rao VK; Ow JR; Lim HJ; Chakraborty P; Vasudevan M; Dhamne CA; Chang KT; Min VL; Kundu TK; Taneja R
J Pathol; 2016 Nov; 240(3):269-281. PubMed ID: 27453350
[TBL] [Abstract][Full Text] [Related]
23. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma.
Jothi M; Mal M; Keller C; Mal AK
Mol Cancer Ther; 2013 Dec; 12(12):2663-74. PubMed ID: 24107448
[TBL] [Abstract][Full Text] [Related]
24. Distinct methylation profiles characterize fusion-positive and fusion-negative rhabdomyosarcoma.
Sun W; Chatterjee B; Wang Y; Stevenson HS; Edelman DC; Meltzer PS; Barr FG
Mod Pathol; 2015 Sep; 28(9):1214-24. PubMed ID: 26226845
[TBL] [Abstract][Full Text] [Related]
25. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
[TBL] [Abstract][Full Text] [Related]
26. Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors.
de Souza RR; Oliveira ID; Caran EM; Alves MT; Abib S; Toledo SR
Growth Horm IGF Res; 2012 Dec; 22(6):245-9. PubMed ID: 23079386
[TBL] [Abstract][Full Text] [Related]
27. Divergent transcriptional and transforming properties of PAX3-FOXO1 and PAX7-FOXO1 paralogs.
Manceau L; Richard Albert J; Lollini PL; Greenberg MVC; Gilardi-Hebenstreit P; Ribes V
PLoS Genet; 2022 May; 18(5):e1009782. PubMed ID: 35604932
[TBL] [Abstract][Full Text] [Related]
28. OLIG2 is a marker of the fusion protein-driven neurodevelopmental transcriptional signature in alveolar rhabdomyosarcoma.
Raghavan SS; Mooney KL; Folpe AL; Charville GW
Hum Pathol; 2019 Sep; 91():77-85. PubMed ID: 31299267
[TBL] [Abstract][Full Text] [Related]
29. Negative correlation of single-cell
Regina C; Hamed E; Andrieux G; Angenendt S; Schneider M; Ku M; Follo M; Wachtel M; Ke E; Kikuchi K; Henssen AG; Schäfer BW; Boerries M; Wagers AJ; Keller C; Hettmer S
Life Sci Alliance; 2021 Sep; 4(9):. PubMed ID: 34187933
[TBL] [Abstract][Full Text] [Related]
30. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma.
Nguyen TH; Barr FG
Molecules; 2018 Oct; 23(11):. PubMed ID: 30373318
[TBL] [Abstract][Full Text] [Related]
32. PAX3-FOXO1 fusion gene in rhabdomyosarcoma.
Linardic CM
Cancer Lett; 2008 Oct; 270(1):10-8. PubMed ID: 18457914
[TBL] [Abstract][Full Text] [Related]
33. MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells.
Cassandri M; Pomella S; Rossetti A; Petragnano F; Milazzo L; Vulcano F; Camero S; Codenotti S; Cicchetti F; Maggio R; Festuccia C; Gravina GL; Fanzani A; Megiorni F; Catanoso M; Marchese C; Tombolini V; Locatelli F; Rota R; Marampon F
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639012
[TBL] [Abstract][Full Text] [Related]
34. Uncovering metabolism in rhabdomyosarcoma.
Monti E; Fanzani A
Cell Cycle; 2016; 15(2):184-95. PubMed ID: 26209235
[TBL] [Abstract][Full Text] [Related]
35. A study of alveolar rhabdomyosarcoma copy number alterations by single nucleotide polymorphism analysis.
Lynn M; Shah N; Conroy J; Ennis S; Morris T; Betts D; O'Sullivan M
Appl Immunohistochem Mol Morphol; 2014 Mar; 22(3):213-21. PubMed ID: 24614150
[TBL] [Abstract][Full Text] [Related]
36. A chimeric RNA characteristic of rhabdomyosarcoma in normal myogenesis process.
Yuan H; Qin F; Movassagh M; Park H; Golden W; Xie Z; Zhang P; Sklar J; Li H
Cancer Discov; 2013 Dec; 3(12):1394-403. PubMed ID: 24089019
[TBL] [Abstract][Full Text] [Related]
37. CRISPR-Cas9-Mediated Bioluminescent Tagging of Endogenous Proteins by Fluorescent Protein-Assisted Cell Sorting.
Hawley RG; Hawley TS
Methods Mol Biol; 2024; 2779():273-286. PubMed ID: 38526790
[TBL] [Abstract][Full Text] [Related]
38. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions.
Barr FG; Qualman SJ; Macris MH; Melnyk N; Lawlor ER; Strzelecki DM; Triche TJ; Bridge JA; Sorensen PH
Cancer Res; 2002 Aug; 62(16):4704-10. PubMed ID: 12183429
[TBL] [Abstract][Full Text] [Related]
39. Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements.
Vicente-García C; Villarejo-Balcells B; Irastorza-Azcárate I; Naranjo S; Acemel RD; Tena JJ; Rigby PWJ; Devos DP; Gómez-Skarmeta JL; Carvajal JJ
Genome Biol; 2017 Jun; 18(1):106. PubMed ID: 28615069
[TBL] [Abstract][Full Text] [Related]
40. Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials.
Selfe J; Olmos D; Al-Saadi R; Thway K; Chisholm J; Kelsey A; Shipley J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]